Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

CAR immunotherapy for the treatment of infectious diseases: a systematic review

  • Morte-Romea, Elena
  • Pesini, Cecilia
  • Pellejero-Sagastizábal, Galadriel
  • Letona-Giménez, Santiago
  • Martínez-Lostao, Luis
  • Loscos Aranda, Silvia
  • Toyas, Carla
  • Redrado, Sergio
  • Dolader-Ballesteros, Elena
  • Arias, Maykel
  • Galvez, Eva M.
  • Sanz-Pamplona, Rebeca
  • Pardo, Julián
  • Paño-Pardo, Jose Ramón
  • Ramírez-Labrada, Ariel
Immunotherapy treatments aim to modulate the host’s immune response to either mitigate it in inflammatory/autoimmune disease or enhance it against infection or cancer. Among different immunotherapies reaching clinical application during the last years, chimeric antigen receptor (CAR) immunotherapy has emerged as an effective treatment for cancer where different CAR T cells have already been approved. Yet their use against infectious diseases is an area still relatively poorly explored, albeit with tremendous potential for research and clinical application. Infectious diseases represent a global health challenge, with the escalating threat of antimicrobial resistance underscoring the need for alternative therapeutic approaches. This review aims to systematically evaluate the current applications of CAR immunotherapy in infectious diseases and discuss its potential for future applications. Notably, CAR cell therapies, initially developed for cancer treatment, are gaining recognition as potential remedies for infectious diseases. The review sheds light on significant progress in CAR T cell therapy directed at viral and opportunistic fungal infections.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Multiparametric in vitro and in vivo analysis of the safety profile of self-assembling peptides

  • Ramirez-Labrada, Ariel
  • Santiago, Llipsy
  • Pesini, Cecilia
  • Arrieta, Marta
  • Arias, Maykel
  • Calvo Pérez, Adanays
  • Ciulla, Maria Gessica
  • Forouharshad, Mahdi
  • Pardo, Julian
  • Gálvez, Eva M.
  • Gelain, Fabrizio
Self-assembling peptides (SAPs) have gained significant attention in biomedicine because of their unique properties and ability to undergo molecular self-assembly driven by non-covalent interactions. By manipulating their composition and structure, SAPs can form well-ordered nanostructures with enhanced selectivity, stability and biocompatibility. SAPs offer advantages such as high chemical and biological diversity and the potential for functionalization. However, studies concerning its potentially toxic effects are very scarce, a limitation that compromises its potential translation to humans. This study investigates the potentially toxic effects of six different SAP formulations composed of natural amino acids designed for nervous tissue engineering and amenable to ready cross-linking boosting their biomechanical properties. All methods were performed in accordance with the relevant guidelines and regulations. A wound-healing assay was performed to evaluate how SAPs modify cell migration. The results in vitro demonstrated that SAPs did not induce genotoxicity neither skin sensitization. In vivo, SAPs were well-tolerated without any signs of acute systemic toxicity. Interestingly, SAPs were found to promote the migration of endothelial, macrophage, fibroblast, and neuronal-like cells in vitro, supporting a high potential for tissue regeneration. These findings contribute to the development and translation of SAP-based biomaterials for biomedical applications.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Biomarkers of immunotherapy response in patients with non-small-cell lung cancer: microbiota composition, short-chain fatty acids, and intestinal permeability

  • Moratiel-Pellitero, Alba
  • Zapata-García, María
  • Gascón Ruiz, Marta
  • Sesma, Andrea
  • Quílez, Elisa
  • Ramírez-Labrada, Ariel
  • Martínez-Lostao, Luis
  • Domingo, María Pilar
  • Esteban, Patricia
  • Yubero, Alfonso
  • Barbero-Herranz, Raquel
  • Moreno-Blanco, Ana
  • Paño, José Ramón
  • Lastra, Rodrigo
  • Pardo, Julián
  • Isla, Dolores
  • Campo, Rosa del
  • Gálvez, Eva
Immune checkpoint inhibitors have been proposed as the standard treatment for different stages of non-small-cell lung cancer in multiple indications. Not all patients benefit from these treatments, however, and certain patients develop immune-related adverse events. Although the search for predictors of response to these drugs is a major field of research, these issues have yet to be resolved. It has been postulated that microbiota could play a relevant role in conditioning the response to cancer treatments; however, the human factor of intestinal permeability also needs to be considered as it is closely related to the regulation of host–microbiota interaction. In this article, we analyzed the possible relationship between the response to immune checkpoint inhibitors and the onset of immune-related adverse events, gut microbiota status, and intestinal membrane permeability. In a pioneering step, we also measured short-chain fatty acid content in feces. Although the correlation analyses failed to identify predictive biomarkers, even when all variables were integrated, our patients’ microbial gut ecosystems were rich and diverse, and the intestinal barrier’s integrity was preserved. These results add new knowledge on the composition of microbiota and its correlation with barrier permeability and short-chain fatty acids and suggest that more studies are required before these potential biomarkers can be incorporated into the clinical management of patients via immune checkpoint inhibitor treatment.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Selective Detection of Active Extracellular Granzyme A by Using a Novel Fluorescent Immunoprobe with Application to Inflammatory Diseases

  • Senan-Salinas, Ana
  • Comas, Laura
  • Esteban, Patricia
  • Garzón-Tituaña, Marcela
  • Cheng, Zhiming
  • Santiago, Llipsy
  • Domingo, Maria Pilar
  • Ramírez-Labrada, Ariel
  • Paño-Pardo, José Ramón
  • Vendrell, Marc
  • Pardo, Julián
  • Arias, Maykel A.
  • Galvez, Eva M.
Granzymes (Gzms), a family of serine proteases, expressed by immune and nonimmune cells, present perforin-dependent and independent intracellular and extracellular functions. When released in the extracellular space, GzmA, with trypsin-like activity, is involved in the pathophysiology of different inflammatory diseases. However, there are no validated specific systems to detect active forms of extracellular GzmA, making it difficult to assess its biological relevance and potential use as a biomarker. Here, we have developed fluorescence-energy resonance-transfer (FRET)-based peptide probes (FAM-peptide-DABCYL) to specifically detect GzmA activity in tissue samples and biological fluids in both mouse and human samples during inflammatory diseases. An initial probe was developed and incubated with GzmA and different proteases like GzmB and others with similar cleavage specificity as GzmA like GzmK, thrombin, trypsin, kallikrein, or plasmin. After measuring fluorescence, the probe showed very good specificity and sensitivity for human and mouse GzmA when compared to GzmB, its closest homologue GzmK, and with thrombin. The specificity of this probe was further refined by incubating the samples in a coated plate with a GzmA-specific antibody before adding the probe. The results show a high specific detection of soluble GzmA even when compared with other soluble proteases with very similar cleavage specificity like thrombin, GzmK, trypsin, kallikrein, or plasmin, which shows nearly no fluorescence signal. The high specific detection of GzmA was validated, showing that using pure proteins and serum and tissue samples from GzmA-deficient mice presented a significant reduction in the signal compared with WT mice. The utility of this system in humans was confirmed, showing that GzmA activity was significantly higher in serum samples from septic patients in comparison with healthy donors. Our results present a new immunoprobe with utility to detect extracellular GzmA activity in different biological fluids, confirming the presence of active forms of the soluble protease in vivo during inflammatory and infectious diseases.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

The importance of murine phospho-MLKL-S345 in situ detection for necroptosis assessment in vivo

  • Kelepouras, Konstantinos
  • Saggau, Julia
  • Varanda, Ana Beatriz
  • Zrilic, Matea
  • Kiefer, Christine
  • Rakhsh-Khorshid, Hassan
  • Lisewski, Ina
  • Uranga-Murillo, Iratxe
  • Arias, Maykel
  • Pardo, Julian
  • Tonnus, Wulf
  • Linkermann, Andreas
  • Annibaldi, Alessandro
  • Walczak, Henning
  • Liccardi, Gianmaria
Necroptosis is a caspase-independent modality of cell death implicated in many inflammatory pathologies. The execution of this pathway requires the formation of a cytosolic platform that comprises RIPK1 and RIPK3 which, in turn, mediates the phosphorylation of the pseudokinase MLKL (S345 in mouse). The activation of this executioner is followed by its oligomerisation and accumulation at the plasma-membrane where it leads to cell death via plasma-membrane destabilisation and consequent permeabilisation. While the biochemical and cellular characterisation of these events have been amply investigated, the study of necroptosis involvement in vivo in animal models is currently limited to the use of Mlkl−/− or Ripk3−/− mice. Yet, even in many of the models in which the involvement of necroptosis in disease aetiology has been genetically demonstrated, the fundamental in vivo characterisation regarding the question as to which tissue(s) and specific cell type(s) therein is/are affected by the pathogenic necroptotic death are missing. Here, we describe and validate an immunohistochemistry and immunofluorescence-based method to reliably detect the phosphorylation of mouse MLKL at serine 345 (pMLKL-S345). We first validate the method using tissues derived from mice in which Caspase-8 (Casp8) or FADD are specifically deleted from keratinocytes, or intestinal epithelial cells, respectively. We next demonstrate the presence of necroptotic activation in the lungs of SARS-CoV-infected mice and in the skin and spleen of mice bearing a Sharpin inactivating mutation. Finally, we exclude necroptosis occurrence in the intestines of mice subjected to TNF-induced septic shock. Importantly, by directly comparing the staining of pMLKL-345 with that of cleaved Caspase-3 staining in some of these models, we identify spatio-temporal and functional differences between necroptosis and apoptosis supporting a role of RIPK3 in inflammation independently of MLKL versus the role of RIPK3 in activation of necroptosis.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Reseña (Review)

In-depth analysis of the interplay between oncogenic mutations and NK cell-mediated cancer surveillance in solid tumors

  • Pesini, Cecilia
  • Artal, Laura
  • Paúl Bernal, Jorge
  • Sánchez Martinez, Diego
  • Pardo, Julián
  • Ramírez-Labrada, Ariel
Natural killer (NK) cells play a crucial role in antitumoral and antiviral responses. Yet, cancer cells can alter themselves or the microenvironment through the secretion of cytokines or other factors, hindering NK cell activation and promoting a less cytotoxic phenotype. These resistance mechanisms, often referred to as the “hallmarks of cancer” are significantly influenced by the activation of oncogenes, impacting most, if not all, of the described hallmarks. Along with oncogenes, other types of genes, the tumor suppressor genes are frequently mutated or modified during cancer. Traditionally, these genes have been associated with uncontrollable tumor growth and apoptosis resistance. Recent evidence suggests oncogenic mutations extend beyond modulating cell death/proliferation programs, influencing cancer immunosurveillance. While T cells have been more studied, the results obtained highlight NK cells as emerging key protagonists for enhancing tumor cell elimination by modulating oncogenic activity. A few recent studies highlight the crucial role of oncogenic mutations in NK cell-mediated cancer recognition, impacting angiogenesis, stress ligands, and signaling balance within the tumor microenvironment. This review will critically examine recent discoveries correlating oncogenic mutations to NK cell-mediated cancer immunosurveillance, a relatively underexplored area, particularly in the era dominated by immune checkpoint inhibitors and CAR-T cells. Building on these insights, we will explore opportunities to improve NK cell-based immunotherapies, which are increasingly recognized as promising alternatives for treating low-antigenic tumors, offering significant advantages in terms of safety and manufacturing suitability.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFß and activin A suppression

  • Rea, Anna
  • Santana-Hernández, Sara
  • Villanueva, Javier
  • Sanvicente-García, Marta
  • Cabo, Mariona
  • Suárez-Olmos, Jesús
  • Quimis, Fabricio
  • Qin, Mengjuan
  • Llorens, Eduard
  • Blasco-Benito, Sandra
  • Torralba-Raga, Lamberto
  • Pérez, Lorena
  • Bhattarai, Bishan
  • Alari-Pahissa, Elisenda
  • Georgoudaki, Anna-Maria
  • Balaguer, Francesc
  • Juan, Manel
  • Pardo, Julián
  • Celià-Terrassa, Toni
  • Rovira, Ana
  • Möker, Nina
  • Zhang, Congcong
  • Colonna, Marco
  • Spanholtz, Jan
  • Malmberg, Karl-Johan
  • Montagut, Clara
  • Albanell, Joan
  • Güell, Marc
  • López-Botet
  • Muntasell, Aura
Transforming growth factor beta (TGFβ) and activin A suppress natural killer (NK) cell function and proliferation, limiting the efficacy of adoptive NK cell therapies. Inspired by the partial resistance to TGFβ of NK cells with SMAD4 haploinsufficiency, we used CRISPR–Cas9 for knockout of SMAD4 in human NK cells. Here we show that SMAD4KO NK cells were resistant to TGFβ and activin A inhibition, retaining their cytotoxicity, cytokine secretion and interleukin-2/interleukin-15-driven proliferation. They showed enhanced tumor penetration and tumor growth control, both as monotherapy and in combination with tumor-targeted therapeutic antibodies. Notably, SMAD4KO NK cells outperformed control NK cells treated with a TGFβ inhibitor, underscoring the benefit of maintaining SMAD4-independent TGFβ signaling. SMAD4KO conferred TGFβ resistance across diverse NK cell platforms, including CD19-CAR NK cells, stem cell-derived NK cells and ADAPT-NK cells. These findings position SMAD4 knockout as a versatile and compelling strategy to enhance NK cell antitumor activity, providing a new avenue for improving NK cell-based cancer immunotherapies.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms

  • Pesini, Cecilia
  • Gil-Bellido, Mario
  • Millán, Lorena S.
  • Oñate, Carmen
  • Calvo-Pérez, Adanays
  • Santiago, Llipsy
  • Iglesias, Eldris
  • Bernal, Jorge Paúl
  • Araujo-Voces, Miguel
  • Paz Artigas, Laura
  • García-Martínez, Laura
  • Roig, Francisco J
  • Movilla Meno, Nieves
  • Garcia-Aznar, José Manuel
  • Menéndez-Jandula, Bárbara
  • Olave, María Teresa
  • Azaceta Reinares, Gemma
  • Garrote, Marta
  • Alvarez-Larrán, Alberto
  • Gálvez, Eva M
  • Sánchez Martínez, Diego
  • Arias, Maykel A
  • Pardo, Julian
  • Ramirez-Labrada, Ariel
Background The adoptive transfer of T cells engineered to express chimeric antigen receptors (CAR-T) has shown high efficacy and safety in treating various hematologic malignancies. However, many hematologic disorders, such as BCR::ABL1-negative myeloproliferative neoplasms (MPNs), lack effective treatment options. Some of these neoplasms are marked by a recurrent mutation that results in the expression of mutant calreticulin (mCALR), a neoantigen absent in healthy tissues, making it a highly specific and appealing target for CAR-T cell therapy. Methods Five distinct CARs were designed based on available monoclonal antibody sequences that target mCALR and were subsequently used to generate CAR-T cells. The most effective construct was selected through functional in vitro assays against mCALR-positive cell lines. Its efficacy was then evaluated in cell lines, patient-derived cells, and orthotopic xenograft models, assessing tumor burden, CAR-T cell infiltration, and animal survival. Bulk and single-cell RNA sequencing were performed on patient-derived cells and residual tumor cells from CART-treated mice, respectively, to investigate potential resistance mechanisms. The impact of the most relevant pathway alteration on CAR-T efficacy was also analyzed. Pharmacological rescue assays using targeted agents were then conducted. Results Among the five constructs, one demonstrated superior and specific cytotoxicity against mCALR-expressing cells, with no activity against mCALR-negative controls. This CAR-T cell also eliminated patient-derived MPN cells and controlled disease progression in xenograft models, which correlated with the persistence of CAR-T cells and tumor infiltration. Transcriptomic profiling of patient samples and residual tumor cells in spleens of treated mice revealed upregulation of anti-apoptotic proteins. Functional assays confirmed reduced CAR-T efficacy in Bcl-2 high cells, which was restored by co-treatment with venetoclax, indicating a viable combination approach to overcome resistance. Conclusions This study demonstrates, for the first time, the successful targeting of mCALR with CAR-T cells as a therapeutic strategy for MPNs. The chosen construct shows strong preclinical efficacy against established cell lines and patient-derived cells. Additionally, transcriptomic profiling uncovered apoptosis resistance mechanisms and supports a combination strategy with BH3 mimetics, such as venetoclax. These findings provide a compelling rationale for ongoing preclinical development and future clinical application of anti-mCALR CAR-T cells for the treatment of MPNs.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Elevated interstitial fluid pressure promotes spheroid growth and reduces CAR-T therapeutic efficacy in solid tumors

  • Alamán-Díez, Pilar
  • Ferrer-Royo, Silvia
  • Oñate Salafranca, Carmen
  • Martín Compaired, Pablo
  • Balsas, Patricia
  • Pardo, Julián
  • García-Aznar, José Manuel
  • González-Loyola, Alejandra
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest solid tumors and is characterized by aggressive progression, a dense tumor microenvironment (TME), and resistance to conventional therapies. Among the barriers to effective treatments, the presence of elevated interstitial fluid pressure (IFP) may be important for drug penetration and immune cell infiltration. In this work, we present an innovative 3D microfluidic PDAC-on-a-chip that allows the application of IFP in a cell chamber to simulate the TME and evaluate the therapeutic efficacy of CAR-T cells engineered against the receptor EGFR expressed in tumor cells. Elevated IFP was associated with increased tumor spheroid growth, reduced caspase activation and decreased actin remodeling, indicating enhanced tumor resistance. CAR-T cells effectively targeted and eliminated tumor cells in 2D and 3D coculture models under normal pressure conditions. However, under high IFP, CAR-Tmediated cytotoxicity was impaired, indicating that some of the low efficacy of CAR-T cell therapy against solid tumors might be derived from IFP. These results highlight the importance of the mechanoenvironment in limiting the efficacy of current immunotherapies. Our model, which incorporates an IFP component, serves as a realistic preclinical platform for testing antitumor therapies in solid tumors. Statement of Significance: In this work, we present an innovative 3D pancreatic tumor-on-a-chip model that incorporates interstitial fluid pressure (IFP), which is a key mechanical component of solid tumors. Using this platform, we discovered that IFP enhances tumor proliferation whilst diminishing immunotherapy efficacy. This indicates the important role of mechanical pressure in limiting immune cell function in solid tumors. Our model is a valuable preclinical platform for investigating the efficacy of anti-tumor therapies and supports the development of strategies to overcome mechanical resistance and enhance therapy efficacy in solid tumors, such as pancreatic cancer.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Lytic IFNγ is stored in cytotoxic granules and coreleased with granzyme B to mediate cytotoxic T lymphocyte killing

  • Li, Xuemei
  • Schirra, Claudia
  • Wirkner, Marie-Louise
  • Tu, Szu-Min
  • Lin, Chin-Hsin
  • Hohmann, Meltem
  • Gu, Yuan
  • Santiago, Llipsy
  • Pardo, Julian
  • Arretxe, Iñaki
  • Alawar, Nadia
  • Chouaib, Abed Alrahman
  • Becherer, Ute
  • Lee, Po-Hsien
  • Hsu, Hao-Jen
  • Laschke, Matthias W.
  • Baldari, Cosima T.
  • Dustin, Michael L.
  • Rettig, Jens
  • Krause, Elmar
  • Chang, Hsin-Fang
Cytotoxic T lymphocytes (CTLs) eliminate target cells by forming immunological synapses and releasing effector molecules, including interferon gamma (IFNγ). However, how IFNγ contributes to cytotoxicity remains unclear. Here, we identify a subset of IFNγ stored within granzyme B⁺ cytotoxic granules (CGs) in activated mouse and human CTLs, which we term lytic IFNγ. This CG-associated IFNγ represents the primary pool released in a polarized manner at the immunological synapse together with canonical lytic molecules. Lytic IFNγ is present in tumor-infiltrating CTLs and is cosecreted with granzyme B (GzmB) in both soluble form and as part of supramolecular attack particles (SMAPs). Functional assays indicate that IFNγ contributes to CTL-mediated tumor cell death by acting in concert with granzyme B and perforin to increase cytotoxicity and promote apoptosis via the IFNγ–STAT1–caspase-3 pathway. CTLs lacking the vesicle priming factor Munc13-4 exhibit impaired release of both CGs and early-phase IFNγ. However, prolonged synapse engagement restores IFNγ secretion at distal membrane sites, revealing a second, nonpolarized IFNγ pool. Consistently, endogenous IFNγ is detected in both CG-enriched and multivesicular body (MVB)-enriched fractions. We propose that while lytic IFNγ is released from CGs at the synapse to directly promote target cell killing, nonpolarized IFNγ secretion originates from MVBs or small vesicles during sustained activation. Together, these findings reveal a previously unrecognized mechanism of IFNγ storage and release, establishing lytic IFNγ as a critical effector component of CTL cytotoxicity and antitumor immunity.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Circulating granzyme A is elevated within the dysregulated host response and associates with mortality in abdominal sepsis

  • Pellejero-Sagastizabal, Galadriel
  • Esteban, Patricia
  • Letona-Giménez, Santiago
  • Andrés-Tovar, Alejandro
  • Sierra, José Luis
  • Senan-Salinas, Ana
  • Galvez, Eva María
  • Pardo, Julián
  • Morte-Romea, Elena
  • Arias, Maykel
  • Paño-Pardo, José Ramón
Introduction Granzyme A (GzmA) has been identified as a key amplifier of sepsis-related inflammation in experimental models without contributing to pathogen clearance. However, its behavior and clinical relevance in human bacterial sepsis remain unknown. We aimed to characterize circulating GzmA in secondary peritonitis and explore its associations with clinical severity and all-cause mortality. Methods We conducted a single-center prospective cohort study of 42 adults with secondary peritonitis at Lozano Blesa Clinical Hospital (Zaragoza, Spain), with 31 healthy controls. Peripheral blood was obtained at baseline, 24 h, and 48 h. Serum GzmA concentration and activity, GzmB, cytokines, and endothelial and coagulation markers were measured. Analyses included comparisons across Sepsis-3 severity strata and exploratory prognostic models (logistic regression and receiver operating characteristic curves) evaluating associations between baseline biomarkers and mortality. Sensitivity analyses were performed after excluding patients meeting predefined immunosuppression criteria. Results At baseline, GzmA concentrations (2.3-fold, q-value = 5.41×10−12) and GzmA enzymatic activity (q-value = 6.75 × 10-³) were significantly higher in patients than controls, whereas GzmB did not differ (q-value = 0.332). Across baseline severity categories, VCAM-1 showed the clearest gradient (q-value = 0.017), while GzmA concentrations were numerically highest in septic shock (median 165.4 pg/mL). GzmA remained elevated through 48 h, and non-survivors had higher baseline levels than survivors. Each doubling of baseline GzmA was associated with higher overall in-hospital mortality (OR 2.52; 95% CI 1.11-5.75, p=0.028), with associations persisting after adjustment for age and comorbidity. Sensitivity analyses excluding immunosuppressed patients yielded a clearer association between GzmA and baseline severity, and confirmed its association with mortality. Discussion Circulating GzmA, but not GzmB, is markedly upregulated, remains elevated during early follow-up, and is preliminarily associated with mortality-related outcomes. These exploratory findings are consistent with experimental models and support further evaluations of extracellular GzmA to investigate its biological and potential translational relevance in sepsis.